Company Overview
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Why Investors Should Care
Net profit has compounded at 50.3% per year over the last five years.
Revenue has grown at a 12.0% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $441.33M (+13.6% YoY); net profit $9.77M.
- Trailing 12 Months Year-on-year growth — revenue +17.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.0%, profit CAGR 50.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.04% |
| 1 Year: | 17.50% |
Compounded Profit Growth
| 5 Years: | 50.30% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -23.26% |
| 6 Months: | -43.32% |
| 3 Months: | -35.94% |
| 1 Month: | +20.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.69 · Neutral
P/E of 97.24 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.0% over 5 years.
- Profit CAGR of 50.3% over 5 years.
CONS
- Trading at a high P/E of 97.2.
- Trading 49.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AORT Artivion, Inc. R2K | 24.31 | 97.24 | $1.18B | 0.00% | 5.28% | 3.14% | 12.04% | 50.30% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 45.06M | 47.82M | 44.00M | - | 61.95M | 68.50M | 64.60M | - | 67.50M | 71.14M | 67.88M | - | 66.43M | 53.77M | 65.13M | 71.09M | 76.15M | 72.21M | 77.21M | 80.34M | 76.84M | 83.23M | 89.25M | 87.85M | 97.43M | 98.02M | - | - | 98.98M | 112.97M | 113.39M | 115.99M | 116.34M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.40M | 39.86M | 38.99M | 42.85M | 40.89M |
| Gross Profit | 21.55M | 22.98M | 26.52M | 27.62M | 30.30M | 29.78M | 31.20M | 29.51M | 32.91M | 29.86M | 36.36M | 39.23M | 45.85M | 42.71M | 45.19M | 44.27M | 46.97M | 45.22M | 46.55M | 44.17M | 35.89M | 43.13M | 47.84M | 50.51M | 47.79M | 50.72M | 52.17M | 48.74M | 53.73M | 58.08M | 56.27M | 62.95M | 63.32M | - | - | 63.58M | 73.11M | 74.39M | 73.14M | 75.45M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.43M | 64.73M | 65.36M | 65.96M | 69.66M |
| Operating Income | -457.00K | 2.53M | - | 6.65M | 4.59M | 5.48M | - | 2.55M | 4.79M | 829.00K | - | -3.49M | 5.41M | 4.62M | - | 2.21M | 6.50M | 4.70M | - | -1.19M | -1.92M | 3.63M | 1.45M | 1.32M | 14.69M | 1.64M | 4.54M | -4.11M | -3.86M | 7.67M | -1.24M | 25.31M | 6.51M | - | - | 2.15M | 8.38M | 9.04M | 7.18M | 5.79M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.81M | 16.29M | 18.89M | 17.82M | 12.05M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.66M | 7.27M | 6.12M | 5.53M | 5.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.29M | 3.48M | 7.06M | 6.54M | 339.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.79M | 2.14M | 554.00K | 4.11M | -1.08M |
| Net Income | -502.00K | 2.15M | 2.64M | 2.54M | 2.35M | 2.99M | 2.90M | 2.22M | 3.16M | 1.32M | -3.01M | -3.85M | 226.00K | 1.56M | -776.00K | -297.00K | 2.83M | -134.00K | -681.00K | -6.67M | -3.69M | -2.87M | -3.14M | -2.18M | 10.58M | -3.39M | -4.26M | -13.71M | -13.53M | -3.38M | -9.80M | 7.53M | -2.12M | - | - | -505.00K | 1.34M | 6.50M | 2.43M | 1.42M |
| Diluted EPS | -0.02 | 0.07 | 0.09 | 0.08 | 0.07 | 0.09 | 0.09 | 0.06 | 0.09 | 0.04 | -0.09 | -0.11 | 0.01 | 0.04 | -0.02 | -0.01 | 0.07 | 0.00 | -0.02 | -0.18 | -0.10 | -0.08 | -0.08 | -0.06 | 0.26 | -0.08 | -0.11 | -0.34 | -0.33 | -0.08 | -0.24 | 0.18 | -0.05 | - | - | -0.01 | 0.03 | 0.13 | 0.05 | 0.03 |
| R&D Expense | 2.68M | 2.96M | - | 2.61M | 3.28M | 3.71M | - | 4.09M | 4.73M | 4.28M | - | 5.37M | 5.72M | 5.22M | - | 5.55M | 5.84M | 6.26M | - | 6.36M | 5.52M | 5.75M | 7.75M | 8.36M | 9.97M | 10.13M | 8.65M | 11.80M | 7.22M | 7.42M | 6.42M | 6.95M | 7.50M | 6.61M | - | 6.73M | 7.06M | 8.08M | - | 8.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 111.69M | 116.64M | 119.63M | 131.72M | 140.76M | 144.64M | 145.90M | 180.38M | 189.70M | 262.84M | 276.22M | 253.23M | 298.84M | 313.79M | 354.00M | 388.54M | 441.33M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.27M | 124.83M | 139.76M | 157.10M |
| Gross Profit | 69.77M | 68.37M | 75.84M | 85.02M | 90.39M | 91.29M | 90.72M | 118.90M | 128.64M | 172.98M | 183.01M | 167.78M | 197.51M | 202.52M | 229.18M | 248.78M | 284.23M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 196.32M | 237.68M | 209.91M | 257.48M |
| Operating Income | 14.50M | 9.87M | 11.64M | 12.61M | 13.82M | 8.84M | 5.35M | 21.82M | 7.97M | 9.31M | 17.04M | 2.44M | 8.12M | 6.20M | -8.51M | 38.87M | 26.75M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.68M | 26.79M | 50.97M | 63.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.22M | 25.30M | 34.28M | 26.58M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.98M | -21.59M | -7.51M | 14.78M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.21M | 9.10M | 5.84M | 5.01M |
| Net Income | 8.68M | 3.94M | 7.37M | 7.95M | 16.17M | 7.32M | 4.00M | 10.78M | 3.70M | -2.84M | 1.72M | -16.68M | -14.83M | -19.19M | -30.69M | -13.36M | 9.77M |
| Diluted EPS | 0.30 | 0.14 | 0.26 | 0.28 | 0.57 | 0.25 | 0.14 | 0.32 | 0.11 | -0.08 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.21 |
| R&D Expense | 5.25M | 5.92M | 6.90M | 7.26M | 8.45M | 8.70M | 10.44M | 13.45M | 19.46M | 23.10M | 22.96M | 24.21M | 35.55M | 38.88M | 28.71M | 28.45M | 30.99M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 137.44M | 147.86M | 157.16M | 174.68M | 176.16M | 181.18M | 316.14M | 589.69M | 571.09M | 605.65M | 789.40M | - | 762.80M | 792.40M | 789.10M | 884.80M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 247.33M | 280.67M | 290.08M | 358.08M |
| Cash & Equivalents | 17.20M | 30.12M | 35.50M | 21.70M | 13.01M | 37.64M | 33.38M | 37.59M | 56.64M | 39.98M | 41.49M | 33.77M | 61.41M | - | 39.35M | 58.94M | 53.46M | 64.91M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.48M | 81.98M | 79.77M | 92.43M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.82M | 71.80M | 79.46M | 89.76M |
| Total Liabilities | - | - | 23.50M | 26.33M | 29.04M | 29.94M | 27.47M | 25.93M | 107.16M | 312.63M | 296.02M | 319.96M | 460.69M | - | 478.47M | 510.62M | 512.90M | 436.56M |
| Current Liabilities | - | - | 19.33M | 21.46M | 21.43M | 20.72M | 20.63M | 19.61M | 30.10M | 42.94M | 34.52M | 45.20M | 60.47M | - | 49.67M | 57.86M | 66.82M | 101.56M |
| Long Term Debt | - | - | - | - | - | - | - | - | 67.01M | 218.24M | 215.72M | 214.57M | 290.47M | - | 306.50M | 305.53M | 314.15M | 215.11M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 356.83M | 358.34M | 362.26M | 257.61M |
| Total Equity | 98.37M | 110.45M | 113.94M | 121.54M | 128.11M | 144.75M | 148.69M | 155.25M | 208.98M | 277.06M | 275.07M | 285.70M | 328.71M | - | 284.33M | 281.78M | 276.20M | 448.23M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.83M | 42.57M | 43.43M | 49.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 16.57M | 20.84M | 16.75M | 18.99M | - | - | 11.44M | 19.72M | 10.80M | 9.88M | 15.83M | 12.37M | - | -5.15M | 18.82M | 22.24M | 39.88M |
| Investing Cash Flow | -4.38M | -10.73M | -27.72M | -22.92M | - | - | -4.49M | -78.91M | -171.05M | -6.71M | -23.94M | -73.13M | - | -10.71M | -502.00K | -28.19M | -42.04M |
| Financing Cash Flow | 707.00K | -4.72M | -2.85M | -4.71M | - | - | -2.81M | 73.43M | 143.25M | -2.56M | -1.49M | 93.61M | - | -1.64M | 865.00K | 2.20M | 11.28M |
| Capital Expenditure | -1.69M | -2.12M | -2.54M | -3.07M | -4.34M | -4.31M | -3.49M | -6.20M | -6.63M | -5.79M | -8.07M | -7.33M | - | -10.71M | -9.75M | -11.19M | -39.04M |
| Free Cash Flow | 14.88M | 18.72M | 14.21M | 15.92M | - | - | 7.95M | 13.52M | 4.17M | 4.09M | 7.75M | 5.04M | - | -15.87M | 9.07M | 11.05M | 839.00K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.51M | 19.19M | -3.75M | 9.12M |
| Share Buybacks | 330.00K | 5.88M | 3.06M | 3.31M | 1.52M | 5.59M | - | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | 1.37M | 2.97M | 3.29M | 3.41M | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 62.5% | 58.6% | 63.4% | 64.5% | 64.2% | 63.1% | 62.2% | 65.9% | 67.8% | 65.8% | 66.3% | 66.3% | 66.1% | 64.5% | 64.7% | 64.0% | 64.4% |
| Operating Margin % | 13.0% | 8.5% | 9.7% | 9.6% | 9.8% | 6.1% | 3.7% | 12.1% | 4.2% | 3.5% | 6.2% | 1.0% | 2.7% | 2.0% | -2.4% | 10.0% | 6.1% |
| Net Margin % | 7.8% | 3.4% | 6.2% | 6.0% | 11.5% | 5.1% | 2.7% | 6.0% | 2.0% | -1.1% | 0.6% | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
| ROE % | 7.9% | 3.5% | 6.1% | 6.2% | 11.2% | 4.9% | 2.6% | 5.2% | 1.3% | -1.0% | 0.6% | -5.1% | - | -6.7% | -10.9% | -4.8% | 2.2% |
| ROCE % | - | 8.4% | 9.2% | 9.3% | 9.0% | 5.7% | 3.3% | 7.6% | 1.5% | 1.7% | 3.0% | 0.3% | - | 0.9% | -1.2% | 5.4% | 3.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.34% | 6.47M | $149.76M |
| 2 | FMR, LLC | 5.32% | 2.58M | $59.75M |
| 3 | Nomura Asset Management International Inc | 5.06% | 2.46M | $56.81M |
| 4 | Morgan Stanley | 4.67% | 2.27M | $52.49M |
| 5 | Vanguard Capital Management LLC | 4.02% | 1.95M | $45.15M |
| 6 | State Street Corporation | 3.47% | 1.68M | $38.91M |
| 7 | Perceptive Advisors Llc | 3.37% | 1.64M | $37.87M |
| 8 | Fred Alger Management, LLC | 2.49% | 1.21M | $27.95M |
| 9 | Juniper Investment Company, LLC | 2.45% | 1.19M | $27.50M |
| 10 | Conestoga Capital Advisors, LLC | 2.42% | 1.18M | $27.19M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AORT
3 Reasons to Sell AORT and 1 Stock to Buy Instead
Artivion’s stock price has taken a beating over the past six months, shedding 43.8% of its value and falling to $24.10 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move.…
3 Stocks Under $50 with Warning Signs
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale adva…
2 Growth Stocks Set to Flourishand 1 We Ignore
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.…
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybri…
3 Profitable Stocks We Keep Off Our Radar
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
AORT — Frequently Asked Questions
What is the current share price of Artivion, Inc. (AORT)?
As of 2026-07-15 16:51 PDT, Artivion, Inc. (AORT) trades at $24.31 on NYSE. Its 52-week range is $20.10 to $47.63.
What is the market capitalisation of AORT?
Artivion, Inc. (AORT) has a market capitalisation of $1.18B on NYSE.
What is the P/E ratio of AORT?
AORT trades at a trailing price-to-earnings (P/E) ratio of 97.24. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.49.
What is the return on equity (ROE) of AORT?
AORT has a return on equity (ROE) of 3.14%. Its return on capital employed (ROCE) is 5.28%.
Is AORT a good stock to buy?
This page provides a data-driven analysis of Artivion, Inc. (AORT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.